 | • レポートコード：QYR9ST01381 • 出版社/出版日：QYResearch / 2019年9月2日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、111ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医薬品・医療 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| ※本調査レポートでは、世界のがんモノクローナル抗体市場について調査・分析し、以下の構成でお届け致します。がんモノクローナル抗体の種類別には、マウス抗体、キメラおよびヒト化抗体、完全ヒト化抗体、その他に、用途別には、肝臓、乳房、血液、脳、ホジキンおよび非ホジキンリンパ腫、結腸直腸、白血病、その他に、地域別には、北米、アメリカ、ヨーロッパ、アジア、中国、日本国内、韓国、インド、中南米、中東・アフリカなどに区分してセグメント分析を行いました。 ・調査販売 ・エグゼクティブ・サマリー ・企業別がんモノクローナル抗体売上データ ・地域別がんモノクローナル抗体市場規模：北米、アメリカ、ヨーロッパ、アジア、中国、日本国内、韓国、インド、中南米、中東・アフリカ、その他 ・種類別がんモノクローナル抗体市場規模：マウス抗体、キメラおよびヒト化抗体、完全ヒト化抗体、その他 ・用途別がんモノクローナル抗体市場規模：肝臓、乳房、血液、脳、ホジキンおよび非ホジキンリンパ腫、結腸直腸、白血病、その他 ・主要メーカーの企業情報：F. Hoffmann-La Roche、Amgen、Bristol-Myers Squibb、Takeda Pharmaceuticals ・がんモノクローナル抗体の市場規模予測 ・バリューチェーン及び販売チャネル分析 ・市場機会・課題・リスク・影響因子分析 ... |
The mAbs, which are produced by genetic engineering, target antigens in cells, tissues, and organs. They are used in clinical applications to treat diseases with excellent efficacy and minimal side effects. Their MOA, absence of generic pathway, and therapeutic applications distinguish them from other targeted therapeutics.Cancer is one of the leading causes of death globally. There were 10.9 million new cases, in 2002, which increased to 14.1 million, in 2012 (approximately 30% growth in a decade). The WHO expects this number to increase by 70%, over the next two decades. According to the WHO, almost 70% of deaths occur in low and middle-income countries. The increment in data is expected to provide the basis for any national policy on cancer, leading to an increase in the percentage of people choosing cancer treatment. In the healthcare sector, cancer is one of the biggest concerns. Thus, the increased use of monoclonal antibodies for the treatment of cancer is driving this market.
Monoclonal Antibodies having the potential to offer less toxic and efficient therapeutic alternatives to the patients have been emerging in the recent years. Monoclonal Antibodies are used to treat a wide array of diseases related to autoimmune, inflammatory and especially cancer. Monoclonal Antibodies (mAbs) are mono-specific antibodies bodies comprising of identical immune cells that are clones of a single parent cells and are directed to a specific cellular targets. Thus Monoclonal Antibodies are highly customizable due to its specific nature and can play a crucial role in eliminating the cancerous cell while sparing the normal cells during the cancer treatment. The monoclonal antibodies are proved to be more effective than chemotherapies and drugs for cancer treatment.
The global Cancer Monoclonal Antibodies market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Cancer Monoclonal Antibodies market based on company, product type, end user and key regions.
This report studies the global market size of Cancer Monoclonal Antibodies in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Cancer Monoclonal Antibodies in these regions.
This research report categorizes the global Cancer Monoclonal Antibodies market by top players/brands, region, type and end user. This report also studies the global Cancer Monoclonal Antibodies market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
F. Hoffmann-La Roche
Amgen
Bristol-Myers Squibb
Takeda Pharmaceuticals
Market size by Product
Murine Antibodies
Chimeric and Humanised Antibodies
Fully Humanized Antibodies
Others
Market size by End User
Liver
Breast
Blood
Brain
Hodgkins and Non-Hodgkins lymphoma
Colorectal
Leukaemia
Others
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Cancer Monoclonal Antibodies market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Cancer Monoclonal Antibodies market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Cancer Monoclonal Antibodies companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Cancer Monoclonal Antibodies submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Cancer Monoclonal Antibodies are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Cancer Monoclonal Antibodies market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
レポート目次Table of Contents
1 Study Coverage
1.1 Cancer Monoclonal Antibodies Product
1.2 Market Segments
1.3 Key Manufacturers Covered
1.4 Market by Type
1.4.1 Global Cancer Monoclonal Antibodies Market Size Growth Rate by Product
1.4.2 Murine Antibodies
1.4.3 Chimeric and Humanised Antibodies
1.4.4 Fully Humanized Antibodies
1.4.5 Others
1.5 Market by End User
1.5.1 Global Cancer Monoclonal Antibodies Market Size Growth Rate by End User
1.5.2 Liver
1.5.3 Breast
1.5.4 Blood
1.5.5 Brain
1.5.6 Hodgkins and Non-Hodgkins lymphoma
1.5.7 Colorectal
1.5.8 Leukaemia
1.5.9 Others
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Cancer Monoclonal Antibodies Market Size
2.1.1 Global Cancer Monoclonal Antibodies Revenue 2014-2025
2.1.2 Global Cancer Monoclonal Antibodies Sales 2014-2025
2.2 Cancer Monoclonal Antibodies Growth Rate by Regions
2.2.1 Global Cancer Monoclonal Antibodies Sales by Regions
2.2.2 Global Cancer Monoclonal Antibodies Revenue by Regions
3 Breakdown Data by Manufacturers
3.1 Cancer Monoclonal Antibodies Sales by Manufacturers
3.1.1 Cancer Monoclonal Antibodies Sales by Manufacturers
3.1.2 Cancer Monoclonal Antibodies Sales Market Share by Manufacturers
3.1.3 Global Cancer Monoclonal Antibodies Market Concentration Ratio (CR5 and HHI)
3.2 Cancer Monoclonal Antibodies Revenue by Manufacturers
3.2.1 Cancer Monoclonal Antibodies Revenue by Manufacturers (2014-2019)
3.2.2 Cancer Monoclonal Antibodies Revenue Share by Manufacturers (2014-2019)
3.3 Cancer Monoclonal Antibodies Price by Manufacturers
3.4 Cancer Monoclonal Antibodies Manufacturing Base Distribution, Product Types
3.4.1 Cancer Monoclonal Antibodies Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Cancer Monoclonal Antibodies Product Type
3.4.3 Date of International Manufacturers Enter into Cancer Monoclonal Antibodies Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
4.1 Global Cancer Monoclonal Antibodies Sales by Product
4.2 Global Cancer Monoclonal Antibodies Revenue by Product
4.3 Cancer Monoclonal Antibodies Price by Product
5 Breakdown Data by End User
5.1 Overview
5.2 Global Cancer Monoclonal Antibodies Breakdown Data by End User
6 North America
6.1 North America Cancer Monoclonal Antibodies by Countries
6.1.1 North America Cancer Monoclonal Antibodies Sales by Countries
6.1.2 North America Cancer Monoclonal Antibodies Revenue by Countries
6.1.3 United States
6.1.4 Canada
6.1.5 Mexico
6.2 North America Cancer Monoclonal Antibodies by Product
6.3 North America Cancer Monoclonal Antibodies by End User
7 Europe
7.1 Europe Cancer Monoclonal Antibodies by Countries
7.1.1 Europe Cancer Monoclonal Antibodies Sales by Countries
7.1.2 Europe Cancer Monoclonal Antibodies Revenue by Countries
7.1.3 Germany
7.1.4 France
7.1.5 UK
7.1.6 Italy
7.1.7 Russia
7.2 Europe Cancer Monoclonal Antibodies by Product
7.3 Europe Cancer Monoclonal Antibodies by End User
8 Asia Pacific
8.1 Asia Pacific Cancer Monoclonal Antibodies by Countries
8.1.1 Asia Pacific Cancer Monoclonal Antibodies Sales by Countries
8.1.2 Asia Pacific Cancer Monoclonal Antibodies Revenue by Countries
8.1.3 China
8.1.4 Japan
8.1.5 Korea
8.1.6 India
8.1.7 Australia
8.1.8 Indonesia
8.1.9 Malaysia
8.1.10 Philippines
8.1.11 Thailand
8.1.12 Vietnam
8.1.13 Singapore
8.2 Asia Pacific Cancer Monoclonal Antibodies by Product
8.3 Asia Pacific Cancer Monoclonal Antibodies by End User
9 Central & South America
9.1 Central & South America Cancer Monoclonal Antibodies by Countries
9.1.1 Central & South America Cancer Monoclonal Antibodies Sales by Countries
9.1.2 Central & South America Cancer Monoclonal Antibodies Revenue by Countries
9.1.3 Brazil
9.2 Central & South America Cancer Monoclonal Antibodies by Product
9.3 Central & South America Cancer Monoclonal Antibodies by End User
10 Middle East and Africa
10.1 Middle East and Africa Cancer Monoclonal Antibodies by Countries
10.1.1 Middle East and Africa Cancer Monoclonal Antibodies Sales by Countries
10.1.2 Middle East and Africa Cancer Monoclonal Antibodies Revenue by Countries
10.1.3 GCC Countries
10.1.4 Turkey
10.1.5 Egypt
10.1.6 South Africa
10.2 Middle East and Africa Cancer Monoclonal Antibodies by Product
10.3 Middle East and Africa Cancer Monoclonal Antibodies by End User
11 Company Profiles
11.1 F. Hoffmann-La Roche
11.1.1 F. Hoffmann-La Roche Company Details
11.1.2 Company Business Overview
11.1.3 F. Hoffmann-La Roche Cancer Monoclonal Antibodies Sales, Revenue and Gross Margin (2014-2019)
11.1.4 F. Hoffmann-La Roche Cancer Monoclonal Antibodies Products Offered
11.1.5 F. Hoffmann-La Roche Recent Development
11.2 Amgen
11.2.1 Amgen Company Details
11.2.2 Company Business Overview
11.2.3 Amgen Cancer Monoclonal Antibodies Sales, Revenue and Gross Margin (2014-2019)
11.2.4 Amgen Cancer Monoclonal Antibodies Products Offered
11.2.5 Amgen Recent Development
11.3 Bristol-Myers Squibb
11.3.1 Bristol-Myers Squibb Company Details
11.3.2 Company Business Overview
11.3.3 Bristol-Myers Squibb Cancer Monoclonal Antibodies Sales, Revenue and Gross Margin (2014-2019)
11.3.4 Bristol-Myers Squibb Cancer Monoclonal Antibodies Products Offered
11.3.5 Bristol-Myers Squibb Recent Development
11.4 Takeda Pharmaceuticals
11.4.1 Takeda Pharmaceuticals Company Details
11.4.2 Company Business Overview
11.4.3 Takeda Pharmaceuticals Cancer Monoclonal Antibodies Sales, Revenue and Gross Margin (2014-2019)
11.4.4 Takeda Pharmaceuticals Cancer Monoclonal Antibodies Products Offered
11.4.5 Takeda Pharmaceuticals Recent Development
12 Future Forecast
12.1 Cancer Monoclonal Antibodies Market Forecast by Regions
12.1.1 Global Cancer Monoclonal Antibodies Sales Forecast by Regions 2019-2025
12.1.2 Global Cancer Monoclonal Antibodies Revenue Forecast by Regions 2019-2025
12.2 Cancer Monoclonal Antibodies Market Forecast by Product
12.2.1 Global Cancer Monoclonal Antibodies Sales Forecast by Product 2019-2025
12.2.2 Global Cancer Monoclonal Antibodies Revenue Forecast by Product 2019-2025
12.3 Cancer Monoclonal Antibodies Market Forecast by End User
12.4 North America Cancer Monoclonal Antibodies Forecast
12.5 Europe Cancer Monoclonal Antibodies Forecast
12.6 Asia Pacific Cancer Monoclonal Antibodies Forecast
12.7 Central & South America Cancer Monoclonal Antibodies Forecast
12.8 Middle East and Africa Cancer Monoclonal Antibodies Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Cancer Monoclonal Antibodies Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Figure Cancer Monoclonal Antibodies Product Picture
Table Cancer Monoclonal Antibodies Market Segments
Table Key Manufacturers Cancer Monoclonal Antibodies Covered
Table Global Cancer Monoclonal Antibodies Market Size Growth Rate by Product 2019-2025 (K Units) & (Million US$)
Figure Global Cancer Monoclonal Antibodies Sales Market Share by Product 2014-2025
Figure Murine Antibodies Product Picture
Table Major Manufacturers of Murine Antibodies
Figure Chimeric and Humanised Antibodies Product Picture
Table Major Manufacturers of Chimeric and Humanised Antibodies
Figure Fully Humanized Antibodies Product Picture
Table Major Manufacturers of Fully Humanized Antibodies
Figure Others Product Picture
Table Major Manufacturers of Others
Table Global Cancer Monoclonal Antibodies Market Size Growth Rate by End User 2019-2025 (K Units)
Figure Liver
Figure Breast
Figure Blood
Figure Brain
Figure Hodgkins and Non-Hodgkins lymphoma
Figure Colorectal
Figure Leukaemia
Figure Others
Figure Cancer Monoclonal Antibodies Report Years Considered
Figure Global Cancer Monoclonal Antibodies Market Size 2014-2025 (Million US$)
Figure Global Cancer Monoclonal Antibodies Sales 2014-2025 (K Units)
Table Global Cancer Monoclonal Antibodies Market Size by Regions 2014-2019 (K Units) & (Million US$)
Table Global Cancer Monoclonal Antibodies Sales by Regions 2014-2019 (K Units)
Table Global Cancer Monoclonal Antibodies Sales Market Share by Regions 2014-2019
Figure Global Cancer Monoclonal Antibodies Sales Market Share by Regions 2014-2019
Figure 2018 Global Cancer Monoclonal Antibodies Sales Market Share by Regions
Table Global Cancer Monoclonal Antibodies Revenue by Regions 2014-2019 (Million US$)
Table Global Cancer Monoclonal Antibodies Revenue Market Share by Regions 2014-2019
Figure Global Cancer Monoclonal Antibodies Revenue Market Share by Regions 2014-2019
Figure 2018 Global Cancer Monoclonal Antibodies Revenue Market Share by Regions
Table Global Cancer Monoclonal Antibodies Sales by Manufacturers (2014-2019) (K Units)
Table Global Cancer Monoclonal Antibodies Sales Share by Manufacturers (2014-2019)
Figure Global Cancer Monoclonal Antibodies Sales Share by Manufacturers in 2018
Table Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table Cancer Monoclonal Antibodies Revenue by Manufacturers (2014-2019) (Million USD)
Table Cancer Monoclonal Antibodies Revenue Share by Manufacturers (2014-2019)
Figure Cancer Monoclonal Antibodies Value Share by Manufacturers in 2018
Table Key Manufacturers Cancer Monoclonal Antibodies Price (2014-2019) (USD/Unit)
Table Cancer Monoclonal Antibodies Manufacturers Manufacturing Base Distribution and Headquarters
Table Manufacturers Cancer Monoclonal Antibodies Product Type
Table Date of International Manufacturers Enter into Cancer Monoclonal Antibodies Market
Table Manufacturers Mergers & Acquisitions, Expansion Plans
Table Global Cancer Monoclonal Antibodies Sales by Product (2014-2019) (K Units)
Table Global Cancer Monoclonal Antibodies Sales Share by Product (2014-2019)
Figure Global Cancer Monoclonal Antibodies Sales Market Share by Product (2014-2019)
Figure Global Cancer Monoclonal Antibodies Sales Market Share by Product in 2018
Table Global Cancer Monoclonal Antibodies Revenue by Product (2014-2019) (Million US$)
Table Global Cancer Monoclonal Antibodies Revenue Share by Product (2014-2019)
Figure Global Cancer Monoclonal Antibodies Revenue Market Share by Product (2014-2019)
Figure Global Cancer Monoclonal Antibodies Revenue Market Share by Product in 2018
Table Cancer Monoclonal Antibodies Price by Product 2014-2019 (USD/Unit)
Table Global Cancer Monoclonal Antibodies Sales by End User (2014-2019) (K Units)
Table Global Cancer Monoclonal Antibodies Sales Share by End User (2014-2019)
Figure Global Sales Cancer Monoclonal Antibodies Market Share by End User (2014-2019)
Figure Global Sales Cancer Monoclonal Antibodies Market Share by End User in 2018
Figure North America Cancer Monoclonal Antibodies Sales Growth Rate 2014-2019 (K Units)
Figure North America Cancer Monoclonal Antibodies Revenue Growth Rate 2014-2019 (Million US$)
Table North America Cancer Monoclonal Antibodies Sales by Countries (2014-2019) (K Units)
Table North America Cancer Monoclonal Antibodies Sales Market Share by Countries (2014-2019)
Figure 2018 North America Cancer Monoclonal Antibodies Sales Market Share by Countries
Table North America Cancer Monoclonal Antibodies Revenue by Countries (2014-2019) (Million US$)
Table North America Cancer Monoclonal Antibodies Revenue Market Share by Countries (2014-2019)
Figure 2018 North America Cancer Monoclonal Antibodies Revenue Market Share by Countries
Figure United States Cancer Monoclonal Antibodies Sales Growth Rate (2014-2019) (K Units)
Figure United States Cancer Monoclonal Antibodies Revenue Growth Rate (2014-2019) (K Units)
Figure Canada Cancer Monoclonal Antibodies Sales Growth Rate (2014-2019) (K Units)
Figure Canada Cancer Monoclonal Antibodies Revenue Growth Rate (2014-2019) (Million US$)
Figure Mexico Cancer Monoclonal Antibodies Sales Growth Rate (2014-2019) (K Units)
Figure Mexico Cancer Monoclonal Antibodies Revenue Growth Rate (2014-2019) (Million US$)
Table North America Cancer Monoclonal Antibodies Sales by Product (2014-2019) (K Units)
Table North America Cancer Monoclonal Antibodies Sales Market Share by Product (2014-2019)
Figure 2018 North America Cancer Monoclonal Antibodies Market Share by Product
Table North America Cancer Monoclonal Antibodies Sales by End User (2014-2019) (K Units)
Table North America Cancer Monoclonal Antibodies Sales Market Share by End User (2014-2019)
Figure 2018 North America Cancer Monoclonal Antibodies Market Share by End User
Figure Europe Cancer Monoclonal Antibodies Sales Growth Rate 2014-2019 (K Units)
Figure Europe Cancer Monoclonal Antibodies Revenue Growth Rate 2014-2019 (Million US$)
Table Europe Cancer Monoclonal Antibodies Sales by Countries (2014-2019) (K Units)
Table Europe Cancer Monoclonal Antibodies Sales Market Share by Countries (2014-2019)
Figure 2018 Europe Cancer Monoclonal Antibodies Sales Market Share by Countries
Table Europe Cancer Monoclonal Antibodies Revenue by Countries (2014-2019) (Million US$)
Table Europe Cancer Monoclonal Antibodies Revenue Market Share by Countries (2014-2019)
Figure 2018 Europe Cancer Monoclonal Antibodies Revenue Market Share by Countries
Figure Germany Cancer Monoclonal Antibodies Sales Growth Rate (2014-2019) (K Units)
Figure Germany Cancer Monoclonal Antibodies Revenue Growth Rate (2014-2019) (Million US$)
Figure France Cancer Monoclonal Antibodies Sales Growth Rate (2014-2019) (K Units)
Figure France Cancer Monoclonal Antibodies Revenue Growth Rate (2014-2019) (Million US$)
Figure UK Cancer Monoclonal Antibodies Sales Growth Rate (2014-2019) (K Units)
Figure UK Cancer Monoclonal Antibodies Revenue Growth Rate (2014-2019) (Million US$)
Figure Italy Cancer Monoclonal Antibodies Sales Growth Rate (2014-2019) (K Units)
Figure Italy Cancer Monoclonal Antibodies Revenue Growth Rate (2014-2019) (Million US$)
Figure Russia Cancer Monoclonal Antibodies Sales Growth Rate (2014-2019) (K Units)
Figure Russia Cancer Monoclonal Antibodies Revenue Growth Rate (2014-2019) (Million US$)
Table Europe Cancer Monoclonal Antibodies Sales by Product (2014-2019) (K Units)
Table Europe Cancer Monoclonal Antibodies Sales Market Share by Product (2014-2019)
Figure 2018 Europe Cancer Monoclonal Antibodies Market Share by Product
Table Europe Cancer Monoclonal Antibodies Sales by End User (2014-2019) (K Units)
Table Europe Cancer Monoclonal Antibodies Sales Market Share by End User (2014-2019)
Figure 2018 Europe Cancer Monoclonal Antibodies Market Share by End User
Figure Asia Pacific Cancer Monoclonal Antibodies Sales Growth Rate 2014-2019 (K Units)
Figure Asia Pacific Cancer Monoclonal Antibodies Revenue Growth Rate 2014-2019 (Million US$)
Table Asia Pacific Cancer Monoclonal Antibodies Sales by Countries (2014-2019) (K Units)
Table Asia Pacific Cancer Monoclonal Antibodies Sales Market Share by Countries (2014-2019)
Figure 2018 Asia Pacific Cancer Monoclonal Antibodies Sales Market Share by Countries
Table Asia Pacific Cancer Monoclonal Antibodies Revenue by Countries (2014-2019) (Million US$)
Table Asia Pacific Cancer Monoclonal Antibodies Revenue Market Share by Countries (2014-2019)
Figure 2018 Asia Pacific Cancer Monoclonal Antibodies Revenue Market Share by Countries
Figure China Cancer Monoclonal Antibodies Sales Growth Rate (2014-2019) (K Units)
Figure China Cancer Monoclonal Antibodies Revenue Growth Rate (2014-2019) (Million US$)
Figure Japan Cancer Monoclonal Antibodies Sales Growth Rate (2014-2019) (K Units)
Figure Japan Cancer Monoclonal Antibodies Revenue Growth Rate (2014-2019) (Million US$)
Figure Korea Cancer Monoclonal Antibodies Sales Growth Rate (2014-2019) (K Units)
Figure Korea Cancer Monoclonal Antibodies Revenue Growth Rate (2014-2019) (Million US$)
Figure India Cancer Monoclonal Antibodies Sales Growth Rate (2014-2019) (K Units)
Figure India Cancer Monoclonal Antibodies Revenue Growth Rate (2014-2019) (Million US$)
Figure Australia Cancer Monoclonal Antibodies Sales Growth Rate (2014-2019) (K Units)
Figure Australia Cancer Monoclonal Antibodies Revenue Growth Rate (2014-2019) (Million US$)
Figure Indonesia Cancer Monoclonal Antibodies Sales Growth Rate (2014-2019) (K Units)
Figure Indonesia Cancer Monoclonal Antibodies Revenue Growth Rate (2014-2019) (Million US$)
Figure Malaysia Cancer Monoclonal Antibodies Sales Growth Rate (2014-2019) (K Units)
Figure Malaysia Cancer Monoclonal Antibodies Revenue Growth Rate (2014-2019) (Million US$)
Figure Philippines Cancer Monoclonal Antibodies Sales Growth Rate (2014-2019) (K Units)
Figure Philippines Cancer Monoclonal Antibodies Revenue Growth Rate (2014-2019) (Million US$)
Figure Thailand Cancer Monoclonal Antibodies Sales Growth Rate (2014-2019) (K Units)
Figure Thailand Cancer Monoclonal Antibodies Revenue Growth Rate (2014-2019) (Million US$)
Figure Vietnam Cancer Monoclonal Antibodies Sales Growth Rate (2014-2019) (K Units)
Figure Vietnam Cancer Monoclonal Antibodies Revenue Growth Rate (2014-2019) (Million US$)
Figure Singapore Cancer Monoclonal Antibodies Sales Growth Rate (2014-2019) (K Units)
Figure Singapore Cancer Monoclonal Antibodies Revenue Growth Rate (2014-2019) (Million US$)
Table Asia Pacific Cancer Monoclonal Antibodies Sales by Product (2014-2019) (K Units)
Table Asia Pacific Cancer Monoclonal Antibodies Sales Market Share by Product (2014-2019)
Figure 2018 Asia Pacific Cancer Monoclonal Antibodies Market Share by Product
Table Asia Pacific Cancer Monoclonal Antibodies Sales by End User (2014-2019) (K Units)
Table Asia Pacific Cancer Monoclonal Antibodies Sales Market Share by End User (2014-2019)
Figure 2018 Asia Pacific Cancer Monoclonal Antibodies Market Share by End User
Figure Central & South America Cancer Monoclonal Antibodies Sales Growth Rate 2014-2019 (K Units)
Figure Central & South America Cancer Monoclonal Antibodies Revenue Growth Rate 2014-2019 (Million US$)
Table Central & South America Cancer Monoclonal Antibodies Sales by Countries (2014-2019) (K Units)
Table Central & South America Cancer Monoclonal Antibodies Sales Market Share by Countries (2014-2019)
Figure 2018 Central & South America Cancer Monoclonal Antibodies Sales Market Share by Countries
Table Central & South America Cancer Monoclonal Antibodies Revenue by Countries (2014-2019) (Million US$)
Table Central & South America Cancer Monoclonal Antibodies Revenue Market Share by Countries (2014-2019)
Figure 2018 Central & South America Cancer Monoclonal Antibodies Revenue Market Share by Countries
Figure Brazil Cancer Monoclonal Antibodies Sales Growth Rate (2014-2019) (K Units)
Figure Brazil Cancer Monoclonal Antibodies Revenue Growth Rate (2014-2019) (Million US$)
Figure Argentina Cancer Monoclonal Antibodies Sales Growth Rate (2014-2019) (K Units)
Figure Argentina Cancer Monoclonal Antibodies Revenue Growth Rate (2014-2019) (Million US$)
Table Central & South America Cancer Monoclonal Antibodies Sales by Product (2014-2019) (K Units)
Table Central & South America Cancer Monoclonal Antibodies Sales Market Share by Product (2014-2019)
Figure 2018 Central & South America Cancer Monoclonal Antibodies Market Share by Product
Table Central & South America Cancer Monoclonal Antibodies Sales by End User (2014-2019) (K Units)
Table Central & South America Cancer Monoclonal Antibodies Sales Market Share by End User (2014-2019)
Figure 2018 Central & South America Cancer Monoclonal Antibodies Market Share by End User
Figure Middle East and Africa Cancer Monoclonal Antibodies Sales Growth Rate 2014-2019 (K Units)
Figure Middle East and Africa Cancer Monoclonal Antibodies Revenue Growth Rate 2014-2019 (Million US$)
Table Middle East and Africa Cancer Monoclonal Antibodies Sales by Countries (2014-2019) (K Units)
Table Middle East and Africa Cancer Monoclonal Antibodies Sales Market Share by Countries (2014-2019)
Figure 2018 Middle East and Africa Cancer Monoclonal Antibodies Sales Market Share by Countries
Table Middle East and Africa Cancer Monoclonal Antibodies Revenue by Countries (2014-2019) (Million US$)
Table Middle East and Africa Cancer Monoclonal Antibodies Revenue Market Share by Countries (2014-2019)
Figure 2018 Middle East and Africa Cancer Monoclonal Antibodies Revenue Market Share by Countries
Figure GCC Countries Cancer Monoclonal Antibodies Sales Growth Rate (2014-2019) (K Units)
Figure GCC Countries Cancer Monoclonal Antibodies Revenue Growth Rate (2014-2019) (Million US$)
Figure Turkey Cancer Monoclonal Antibodies Sales Growth Rate (2014-2019) (K Units)
Figure Turkey Cancer Monoclonal Antibodies Revenue Growth Rate (2014-2019) (Million US$)
Figure Egypt Cancer Monoclonal Antibodies Sales Growth Rate (2014-2019) (K Units)
Figure Egypt Cancer Monoclonal Antibodies Revenue Growth Rate (2014-2019) (Million US$)
Figure South Africa Cancer Monoclonal Antibodies Sales Growth Rate (2014-2019) (K Units)
Figure South Africa Cancer Monoclonal Antibodies Revenue Growth Rate (2014-2019) (Million US$)
Table Middle East and Africa Cancer Monoclonal Antibodies Sales by Product (2014-2019) (K Units)
Table Middle East and Africa Cancer Monoclonal Antibodies Sales Market Share by Product (2014-2019)
Figure 2018 Middle East and Africa Cancer Monoclonal Antibodies Market Share by Product
Table Middle East and Africa Cancer Monoclonal Antibodies Sales by End User (2014-2019) (K Units)
Table Middle East and Africa Cancer Monoclonal Antibodies Sales Market Share by End User (2014-2019)
Figure 2018 Middle East and Africa Cancer Monoclonal Antibodies Market Share by End User
Table F. Hoffmann-La Roche Company Details
Table F. Hoffmann-La Roche Cancer Monoclonal Antibodies Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
Table F. Hoffmann-La Roche Recent Development
Table Amgen Company Details
Table Amgen Cancer Monoclonal Antibodies Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
Table Amgen Recent Development
Table Bristol-Myers Squibb Company Details
Table Bristol-Myers Squibb Cancer Monoclonal Antibodies Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
Table Bristol-Myers Squibb Recent Development
Table Takeda Pharmaceuticals Company Details
Table Takeda Pharmaceuticals Cancer Monoclonal Antibodies Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
Table Takeda Pharmaceuticals Recent Development
Table Global Cancer Monoclonal Antibodies Sales Forecast by Regions 2019-2025 (K Units)
Table Global Cancer Monoclonal Antibodies Sales Market Share Forecast by Regions 2019-2025
Table Global Cancer Monoclonal Antibodies Revenue Forecast by Regions 2019-2025 (Million US$)
Table Global Cancer Monoclonal Antibodies Revenue Market Share Forecast by Regions 2019-2025
Table Global Cancer Monoclonal Antibodies Sales Forecast by Product 2019-2025 (K Units)
Table Global Cancer Monoclonal Antibodies Sales Market Share Forecast by Product 2019-2025
Table Global Cancer Monoclonal Antibodies Revenue Forecast by Product 2019-2025 (Million US$)
Table Global Cancer Monoclonal Antibodies Revenue Market Share Forecast by Product 2019-2025
Table Global Cancer Monoclonal Antibodies Sales Forecast by End User 2019-2025 (K Units)
Table Global Cancer Monoclonal Antibodies Sales Market Share Forecast by End User 2019-2025
Figure North America Cancer Monoclonal Antibodies Sales Growth Rate Forecast (2019-2025) (K Units)
Figure North America Cancer Monoclonal Antibodies Revenue Growth Rate Forecast (2019-2025) (Million US$)
Figure Europe Cancer Monoclonal Antibodies Sales Growth Rate Forecast (2019-2025) (K Units)
Figure Europe Cancer Monoclonal Antibodies Revenue Growth Rate Forecast (2019-2025) (Million US$)
Figure Asia Pacific Cancer Monoclonal Antibodies Sales Growth Rate Forecast (2019-2025) (K Units)
Figure Asia Pacific Cancer Monoclonal Antibodies Revenue Growth Rate Forecast (2019-2025) (Million US$)
Figure Central & South America Cancer Monoclonal Antibodies Sales Growth Rate Forecast (2019-2025) (K Units)
Figure Central & South America Cancer Monoclonal Antibodies Revenue Growth Rate Forecast (2019-2025) (Million US$)
Figure Middle East and Africa Cancer Monoclonal Antibodies Sales Growth Rate Forecast (2019-2025) (K Units)
Figure Middle East and Africa Cancer Monoclonal Antibodies Revenue Growth Rate Forecast (2019-2025) (Million US$)
Table Cancer Monoclonal Antibodies Value Chain
Table Cancer Monoclonal Antibodies Customers List
Table Cancer Monoclonal Antibodies Distributors List
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources
乳がんモノクローナル抗体の世界市場：市場規模・現状・予測 Breast cancer is characterized by the malignancy of cells in the tissues of the breast. HER-2 breast cancer is the most common type of breast cancer. The HER-2 protein, present on the surface of normal breast cells, affects the growth of the malignant cells. The uncontrolled synthesis of this protei…- 世界のバイオシミラーモノクローナル抗体市場：専門的調査 Monoclonal antibodies (mAb) are antibodies produced by using identical immune cells that are clones of one unique parent cell. Since monoclonal antibodies are produced from clones of only one parent cell, all monoclonal antibodies produced by the parent cell are the same due to which, they are calle…
- 世界のがん用二重特異性抗体市場：専門的調査 Bispecific antibodies can simultaneously address two different antigens, which are sufficient to target two trails involved in cancer pathogenesis, and therefore, provide advantages over monoclonal antibodies therapy. The global Bispecific Antibodies for Cancer market was valued at xx million US$ in…
- 組換え治療用抗体及びタンパク質の世界市場：インサイト・予測 Therapeutic proteins are engineered in the laboratory for pharmaceutical use, including non-covalent binders. These proteins are highly effective and serve as modernized treatment for rare as well as chronic diseases. Protein therapeutics offer custom-made treatment approach by supporting a specific…
- ナノ抗体の世界市場：市場規模・現状・予測 Nanoantibodies or "nAb" are single-domain VHH antibodies derived from camelidae (camels, llamas, alpacas, etc.). Compared with conventional monoclonal and polyclonal antibodies, nAbs have the following advantages: Small size (~15kd) High affinity (frequently nanomolar range) High specificity Unsurpa…